Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
Verlagsversion
DOI
 |
|
|
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Longevity, aging and rapamycin.
Cell. Mol. Life Sci. 71, 4325-4346 (2014)
The federal drug administration (FDA)-approved compound rapamycin was the first pharmacological agent shown to extend maximal lifespan in both genders in a mammalian species. A major question then is whether the drug slows mammalian aging or if it has isolated effects on longevity by suppressing cancers, the main cause of death in many mouse strains. Here, we review what is currently known about the effects that pharmacological or genetic mammalian target of rapamycin (mTOR) inhibition have on mammalian aging and longevity. Currently available evidence seems to best fit a model, wherein rapamycin extends lifespan by suppressing cancers. In addition the drug has symptomatic effects on some aging traits, such as age-related cognitive impairments.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Aging ; Anti-aging ; Cancer ; Cardiovascular Disease ; Disease ; Drug ; Lifespan ; Longevity ; Mammalian Target Of Rapamycin ; Mammals ; Mechanism ; Mice ; Mtor ; Neurodegeneration ; Prevention ; Rapamycin ; Treatment
ISSN (print) / ISBN
1420-682X
e-ISSN
1420-9071
Zeitschrift
Cellular and Molecular Life Sciences - CMLS
Quellenangaben
Band: 71,
Heft: 22,
Seiten: 4325-4346
Verlag
Birkhäuser
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed